Issue: August 2018
June 19, 2018
2 min read
Save

Ready-to-drink Solution Superior to Powder for Colonoscopy Bowel Prep

Issue: August 2018
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

WASHINGTON — Clenpiq showed efficacy and safety for patients who undergo colonoscopy, according to research presented at Digestive Disease Week. Additionally, study data revealed the ready-to-drink solution was superior to a powder solution.

Perspective from Carol Burke, MD

“Many patients see colonoscopies as an ordeal they must endure for their overall health,” Lawrence Hookey, MD, of the department of medicine at Queen’s University in Ontario, Canada, said in a press release. “An effective bowel preparation is essential for a successful screening colonoscopy.”

Hookey and colleagues conducted a phase 3, randomized, assessor-blind study to test the non-inferiority and safety of split-dose Clenpiq (sodium picosulfate, magnesium oxide, and citric acid oral solution [SPMC oral solution], Ferring Pharmaceuticals) to a powder solution (P/MC) for colon cleansing in adults.

Investigators randomly assigned 901 patients to receive either the ready-to-drink SPMC oral solution (n = 448) or P/MC powder (n = 453). They assessed overall colon cleansing using the Aronchick scale, and they based efficacy on the proportion of patients with “excellent” or “good” ratings.

SPMC vs. P/MC

The efficacy rate of SPMC oral solution was 87.7% (95% CI, 84.3–90.6), and for P/MC powder it was 81.5% (95% CI, 77.6–84.9; P = .0067).

Regarding safety, no deaths or serious treatment emergent adverse events related to the drug were reported. The adverse event rate for the SPMC solution was 13.2% compared with 16.8% for P/MC powder.

Hookey said their findings showed that the SPMC solution is not only non-inferior to P/MC powder, but superior.

“The data from this study confirm the efficacy of a ready-to-drink treatment option that can help adult patients prepare for their colonoscopy,” he said.

The FDA approved Clenpiq for colonoscopy preparation in December 2017, and it is currently available by prescription. - by Alex Young

Reference:

Hookey L, et al. Poster Tu2010. Presented at: Digestive Disease Week; June 2-5, 2018; Washington, D.C.

Disclosures: Hookey reports financial ties to Ferring Pharmaceuticals and Pentax Medical. Please see the DDW faculty disclosure index for a list of all other authors’ relevant financial disclosures.